Statin intolerance: The cost to the patient

Statin intolerance, most commonly evident as muscle symptoms, is an important issue for clinicians. A new report shows that in high risk patients, the risk of a recurrent heart attack or stroke is at least 50% higher than in patients who adhere to statin therapy. This represents a significant cost not only to the individual but also the healthcare provider.

Read the full report »

PCSK9 Forum talks to Professor Robert S. Rosenson (Mount Sinai Heart, Icahn School of Medicine, New York) about the key issues.

How to diagnose statin intolerance?		How does statin intolerance impact on clinical outcome?

After FOURIER, how do we improve access to PCSK9 inhibitors?
	PCSK9 Forum Co-Editors Professors John Chapman and Henry Ginsberg put FOURIER in the hot seat in this discussion		Professor Dean G. Karalis (Pennsylvania Hospital, USA) discusses the NLA survey: Challenges in PCSK9 inhibitor prescribing